137 related articles for article (PubMed ID: 30552008)
1. Development of an anti-hepatitis B virus (HBV) agent through the structure-activity relationship of the interferon-like small compound CDM-3008.
Takahashi N; Hayashi K; Nakagawa Y; Furutani Y; Toguchi M; Shiozaki-Sato Y; Sudoh M; Kojima S; Kakeya H
Bioorg Med Chem; 2019 Feb; 27(3):470-478. PubMed ID: 30552008
[TBL] [Abstract][Full Text] [Related]
2. An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes.
Furutani Y; Toguchi M; Shiozaki-Sato Y; Qin XY; Ebisui E; Higuchi S; Sudoh M; Suzuki H; Takahashi N; Watashi K; Wakita T; Kakeya H; Kojima S
PLoS One; 2019; 14(6):e0216139. PubMed ID: 31188831
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents.
Tan TM; Chen Y; Kong KH; Bai J; Li Y; Lim SG; Ang TH; Lam Y
Antiviral Res; 2006 Aug; 71(1):7-14. PubMed ID: 16564099
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of imidazo[1,2-α][1,8]naphthyridine derivatives as anti-HCV agents via direct C-H arylation.
Huang S; Qing J; Wang S; Wang H; Zhang L; Tang Y
Org Biomol Chem; 2014 Apr; 12(15):2344-8. PubMed ID: 24595428
[TBL] [Abstract][Full Text] [Related]
5. 4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.
Hwang N; Ban H; Wu S; McGuire K; Hernandez E; Chen J; Zhao Q; Suresh M; Blass B; Viswanathan U; Kulp J; Chang J; Clement J; Menne S; Guo JT; Du Y
Bioorg Med Chem Lett; 2022 Feb; 58():128518. PubMed ID: 34979256
[TBL] [Abstract][Full Text] [Related]
6. Discovery of (1
Wang C; Pei Y; Wang L; Li S; Jiang C; Tan X; Dong Y; Xiang Y; Ma Y; Liu G
J Med Chem; 2020 Jun; 63(11):6066-6089. PubMed ID: 32421339
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and anti-HBV activity evaluation of new substituted imidazo[4,5-b]pyridines.
Gerasi M; Frakolaki E; Papadakis G; Chalari A; Lougiakis N; Marakos P; Pouli N; Vassilaki N
Bioorg Chem; 2020 May; 98():103580. PubMed ID: 32005482
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antiviral effects of isosteviol-derived analogues against the hepatitis B virus.
Huang TJ; Chou BH; Lin CW; Weng JH; Chou CH; Yang LM; Lin SJ
Phytochemistry; 2014 Mar; 99():107-14. PubMed ID: 24461778
[TBL] [Abstract][Full Text] [Related]
9. A review of non-nucleoside anti-hepatitis B virus agents.
Zhang F; Wang G
Eur J Med Chem; 2014 Mar; 75():267-81. PubMed ID: 24549242
[TBL] [Abstract][Full Text] [Related]
10. 1,3,4-oxadiazole: a privileged structure in antiviral agents.
Li Z; Zhan P; Liu X
Mini Rev Med Chem; 2011 Nov; 11(13):1130-42. PubMed ID: 22353222
[TBL] [Abstract][Full Text] [Related]
11. SAR studies in the sulfonyl carboxamide class of HBV capsid assembly modulators.
Kuduk SD; Lam AM; Espiritu C; Vogel R; Lau V; Klumpp K; Flores OA; Hartman GD
Bioorg Med Chem Lett; 2019 Aug; 29(16):2405-2409. PubMed ID: 31227344
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication.
Srivastav NC; Shakya N; Mak M; Agrawal B; Tyrrell DL; Kumar R
J Med Chem; 2010 Oct; 53(19):7156-66. PubMed ID: 20857959
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and bioevaluation of paeonol derivatives as potential anti-HBV agents.
Huang TJ; Chuang H; Liang YC; Lin HH; Horng JC; Kuo YC; Chen CW; Tsai FY; Yen SC; Chou SC; Hsu MH
Eur J Med Chem; 2015 Jan; 90():428-35. PubMed ID: 25461891
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of metachromin A on hepatitis B virus production via impairment of the viral promoter activity.
Yamashita A; Tamaki M; Kasai H; Tanaka T; Otoguro T; Ryo A; Maekawa S; Enomoto N; de Voogd NJ; Tanaka J; Moriishi K
Antiviral Res; 2017 Sep; 145():136-145. PubMed ID: 28827084
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of new 1,2,3-triazolo-2'-deoxy-2'-fluoro- 4'-azido nucleoside derivatives as potent anti-HBV agents.
Liu Y; Peng Y; Lu J; Wang J; Ma H; Song C; Liu B; Qiao Y; Yu W; Wu J; Chang J
Eur J Med Chem; 2018 Jan; 143():137-149. PubMed ID: 29174810
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors.
Qiu J; Gong Q; Gao J; Chen W; Zhang Y; Gu X; Tang D
Eur J Med Chem; 2018 Jan; 144():424-434. PubMed ID: 29288943
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of aminothiazole based Hepatitis B Virus (HBV) capsid inhibitors.
Pan T; Ding Y; Wu L; Liang L; He X; Li Q; Bai C; Zhang H
Eur J Med Chem; 2019 Mar; 166():480-501. PubMed ID: 30739828
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in-vitro anti-hepatitis-B virus activity of 6H-[1]benzothiopyrano[4,3-b] quinolin-10-ols.
Jia W; Zhao Y; Li R; Wu Y; Li Z; Gong P
Arch Pharm (Weinheim); 2009 Sep; 342(9):507-12. PubMed ID: 19637181
[TBL] [Abstract][Full Text] [Related]
19. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
Kumar R; Semaine W; Johar M; Tyrrell DL; Agrawal B
J Med Chem; 2006 Jun; 49(12):3693-700. PubMed ID: 16759112
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
